Replying to @myESMO
@myESMO 2026: Top trending breast cancer oncologists on 𝕏.
Explore #ESMO26 insights here: clin.larvol.com/conference/a…
#LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #BreastCancer #TNBC #BCSM #ClinicalOncology | @PTarantinoMD | @dr_yakupergun | @ErikaHamilton9 | @MamMa_mimumemo | @barriere_dr | @Dr_Oncologista | @stolaney1 | @shimoi_oncology | @drsarahsam | @NeilVasan | @DrSGraff | @DrBarbiOnc | @hoperugo | @Dr_ElvinaA | @to_be_elizabeth
Replying to @myESMO
@myESMO 2026: Most discussed breast cancer trials by influencer posts on 𝕏.
Explore #ESMO26 insights here: clin.larvol.com/conference/a…
#LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #BreastCancer #TNBC #BCSM #ClinicalOncology | @dr_yakupergun | @PTarantinoMD | @MamMa_mimumemo | @Dr_Oncologista | @ErikaHamilton9 | @DrSGraff | @stolaney1 | @ElisaAgostinett | @matteolambe | @E_de_Azambuja
Aya Mohamed | MSc, MD 🎗 retweeted
OUT TODAY!!
THE COMPLETE #ESMO26 NEWSLETTER 📰
Bringing together our top picks from the most important trials presented in Madrid, all in one email.
📩 Register to receive it: buff.ly/N5gYtAc
Curated by oncologists, for colleagues in cancer care, our mission is to make the latest oncology science accessible, relevant, and easy to digest.
We are OncoAlert 🚨 — For Colleagues, by Colleagues.
Best,
The OncoAlert Network
@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3
🤖 Made with AI
Aya Mohamed | MSc, MD 🎗 retweeted
Thank you Colleagues for a phenomenal #ESMO26
ESMO in Madrid is a wrap, and we are grateful to everyone who shared, discussed, debated and amplified the science this week. You turned five days in Madrid into a truly global conversation. 🌍 OUR Network's MISSION: Keep our colleagues worldwide Up To date in REAL TIME.
📣 101.7M impressions of potential reach
💬 6.1K posts on X from 988 participants in 34 countries
⚡ 43.1 posts per hour across the meeting days
😊 45% positive sentiment, with only 6% negative
Real-time metrics powered by ACUVOX. WWW.ACUVOX.IO
🏆 Top influencers
@DrChoueiri, @StephenVLiu, @PTarantinoMD, @dr_yakupergun, @HHorinouchi, @zklaassen_md, @stolaney1, @ArndtVogel, @DrYukselUrun, @DraMartinezLago, @tompowles1, @SuyogCancer, @adamfeuerstein, @ScaltritiLab, @GIMedOnc, @ScottGottliebMD, @barriere_dr, @_ShankarSiva, @miriamgonp, @TiansterZhang, @matteolambe, @NiuSanford, @christine_lovly, @amerseburger, @GlopesMd, @montypal, @Icro_Meattini, @PGrivasMDPhD, @brian_rini, @CathyEngMD, @apolo_andrea, @AndreaNecchi, @DrSGraff, @graokane, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @Lucarecco, @mzugman, @p_ciracimd, @DrVilmaPBarcia, @MarioBalsaMD, @scocmem, @GaiaGriguolo, @JankovicK, @Dr_Oncologista
🌎 Where the conversation came from
North America led with 1,940 posts, followed closely by Europe with 1,777. Boston, Madrid and New York were the most active cities.
🔬 Top studies by impact
1️⃣ DeLLphi-305 (SCLC): 4.0M reach, 170 posts
2️⃣ VOLGA (bladder): 3.7M reach, 141 posts
3️⃣ KRASCENDO-1 (NSCLC): 3.5M reach
4️⃣ SAFFRON (NSCLC): 3.3M reach
5️⃣ INTerpath-001 (melanoma): 154 posts
Pinging our Collaborators
Aya Mohamed | MSc, MD 🎗 retweeted
TroFuse-005, investigational: “That is clinically meaningful and warrants use.” “The tox is a concern.” — @DrKatyMoore
KEYNOTE-C93 (@Merck): “Important caveat: Comparator was chemotherapy alone, NOT the current chemo-immunotherapy standard.” — @SuyogCancer
hubs.ly/Q04CnqTR0
Aya Mohamed | MSc, MD 🎗 retweeted
BFv Showed Activity in Pretreated Metastatic Triple-Negative Breast Cancer After Prior Top1i-ADC Exposure - Aya Mohamed
@Dr_Oncologista
oncodaily.com/science/aya-mo…
Aya Mohamed | MSc, MD 🎗 retweeted
Dear colleagues,
We are already curating THE COMPLETE #ESMO26 NEWSLETTER 📰 our picks of the top trials presented in Madrid, together in one email.
Register to receive it 👉 buff.ly/N5gYtAc
Every newsletter is curated by oncologists, for colleagues working in cancer care. It’s our way of making science quick and accessible.
We are OncoAlert🚨 For Colleagues, by Colleagues
Best,
The Network
@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3
Aya Mohamed | MSc, MD 🎗 retweeted
Day 1 of #ESMO26 💻📚
Following the latest in oncology. 🧬
@OncoAlert
Aya Mohamed | MSc, MD 🎗 retweeted
Replying to @Dr_Oncologista
Grateful to be part of the @OncoAlert faculty and a community built on expertise, collaboration, and a shared commitment to better cancer care. 🇪🇸
#ESMO26 @myESMO
@PGrivasMDPhD @DrSGraff @to_be_elizabeth @ElisaAgostinett @Lucarecco @weoncologists
Aya Mohamed | MSc, MD 🎗 retweeted
“So do we need a biomarker at all here?” — @DrKatyMoore on FONTANA (@AstraZeneca)
“With TOPO1 payloads, the gate is falling.” — @DrBarbiOnc on BEHOLD-1 (@GSK)
DUO-E OS update: @Dr_Oncologista @ChandrakanthMv
#ESMO26 hubs.ly/Q04Cf8kr0
Aya Mohamed | MSc, MD 🎗 retweeted
More than a faculty and more than a network!
The best oncology family I could ask for 🧡
So proud to be part of @OncoAlert and being PULSE at #ESMO26! Learning from brilliant colleagues, sharing the science in real time, and growing together along the way.
By colleagues, for colleagues 🌍
@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOn @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists
The OncoAlert #ESMO26 PULSE! 🇪🇸 WE ARE HERE!
OncoAlert would like to thank our faculty and our #OncoAlertAF
for their amazing coverage of ESMO MADRID!
WE ARE ALL OncoAlert...By Colleagues...For Colleagues
Meet our incredible faculty reporting live from Madrid:
@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists
Whether you're at #ESMO26 in Madrid or following from home, our faculty brings you the latest science, insights, and key updates straight from the congress.
OncoAlert has you covered!
Less noise. No nonsense. Just science.
Aya Mohamed | MSc, MD 🎗 retweeted
The OncoAlert #ESMO26 PULSE! 🇪🇸 WE ARE HERE!
OncoAlert would like to thank our faculty and our #OncoAlertAF
for their amazing coverage of ESMO MADRID!
WE ARE ALL OncoAlert...By Colleagues...For Colleagues
Meet our incredible faculty reporting live from Madrid:
@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists
Whether you're at #ESMO26 in Madrid or following from home, our faculty brings you the latest science, insights, and key updates straight from the congress.
OncoAlert has you covered!
Less noise. No nonsense. Just science.
Aya Mohamed | MSc, MD 🎗 retweeted
A Great Day 3 🇪🇸 at #ESMO26
Thank you @myESMO for a great meeting!!
The oncology conversation from Madrid keeps growing:
Real-time metrics by AcuVox.IO
🔥 61.4M potential reach
💬 4.0K posts on X (clean, no bots/dupes)
👥 797 voices from 31 countries
⚡ 49.4 posts/hour
😊 40% positive sentiment
Europe 🤝 North America neck and neck, with Boston, Madrid & London leading the cities.
Thank you to everyone sharing the science 🙏
@NEJM, @DrChoueiri, @GlopesMd, @weoncologists, @urotoday, @Medscape, @StephenVLiu, @DanaFarber, @NatureMedicine, @MSKCancerCenter, @Annals_Oncology
Pinging our faculty
@cdanicas, @hoperugo, @TiansterZhang, @matteolambe, @NiuSanford, @stolaney1, @christine_lovly, @amerseburger, @GlopesMd, @tompowles1, @montypal, @Icro_Meattini, @PGrivasMDPhD, @brian_rini, @CathyEngMD, @apolo_andrea, @AndreaNecchi, @DrSGraff, @graokane, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, , @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus,
Original Article: Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer (phase 3 HEALER trial) nej.md/4BcWlF3
Editorial: Targeting HER2 — A Triumph of Science nej.md/4Bh4GaF
#ESMO26 | @myESMO

ALT Two panels showing progression-free survival, overall and according to subgroup analyses (intention-to-treat population). Panel A is a graph showing progression-free survival as assessed by blinded independent central review; data are presented as stratified hazard ratio and 95% confidence interval. Panel B is a forest plot showing blinded independent central review–assessed progression-free survival in prespecified subgroups; data are presented as unstratified hazard ratios and 95% confidence intervals.
Aya Mohamed | MSc, MD 🎗 retweeted
Replying to @Dr_Oncologista
@Dr_Oncologista highlighting the DUO-E OS signal is a great prompt to revisit the design. Pearl for fellows: read the olaparib effect within the pMMR group, since dMMR tumors get most of their benefit from durvalumab alone. #ESMO26 #gyncsm
DUO-E #ESMO26
Overall Survival Signals and the Added Value of PARP Inhibition in Advanced Endometrial Cancer
@OncoAlert #ESMOAmbassadors
#ESMOcommunity @myESMO
Aya Mohamed | MSc, MD 🎗 retweeted
Honored to be part of this discussion with OncoDaily and esteemed colleagues on the 6-year NATALEE data and its implications for breast cancer care.
#ESMO26 #BreastCancer @OncoAlert
#ESMOAmbassadors #ESMOcommunity @myESMO
Oncologists Discuss NATALEE Trial
The six-year #NATALEE trial results presented at #ESMO2026 showed an overall survival benefit and sustained improvements in invasive disease-free survival with adjuvant ribociclib plus endocrine therapy in patients with HR+/HER2− early breast cancer.
oncodaily.com/science/natale…
@KefahMokbel @SuyogCancer @emadshash @Timothee_MD @DrBarbiOnc @HundalJasmin @Aydah_AlAwadhi @DrSGraff @dr_yakupergun @kazuki_nozawa @sara_soliman7 @stolaney1 @Dr_Oncologista @DrHBurstein
Aya Mohamed | MSc, MD 🎗 retweeted
Oncologists Discuss NATALEE Trial
The six-year #NATALEE trial results presented at #ESMO2026 showed an overall survival benefit and sustained improvements in invasive disease-free survival with adjuvant ribociclib plus endocrine therapy in patients with HR+/HER2− early breast cancer.
oncodaily.com/science/natale…
@KefahMokbel @SuyogCancer @emadshash @Timothee_MD @DrBarbiOnc @HundalJasmin @Aydah_AlAwadhi @DrSGraff @dr_yakupergun @kazuki_nozawa @sara_soliman7 @stolaney1 @Dr_Oncologista @DrHBurstein
Aya Mohamed | MSc, MD 🎗 retweeted
POP-DURVA試験。
DurvalumabをStage I TNBCに対して、術前に2回投与した71例において、pCRは1例(1.4%)でした。
一方、sTILsは中央値10ポイント増加し、TLSは当初陰性だった49例中16例に新たに出現しています。immune-excludedからinflamed phenotypeへ変化する症例が認められました。
TLSがあることは腫瘍免疫環境にとって良いであろう傾向は見えている一方で、これまで、動的に新たに出現することが臨床成績を上げるかどうかははっきりしていない、ということもあります。
今回は腫瘍免疫微小環境の変化が必ずしも腫瘍消失につながらないことを示す、重要なwindow-of-opportunity研究でした。
今後、日本でもwindow-of-opportunity研究を実施する場合には、治療前後の組織を用いて、単なる免疫細胞数だけではなく、細胞傷害機能、T細胞クローン性、TLS成熟度、腫瘍細胞との空間的位置関係を解析する必要があると考えます。当たり前のトレンドではありますが。。。
#ESMO26
POP-Durva | #ESMO26
Short-course durvalumab reshaped the immune microenvironment in early TNBC, increasing median sTILs from 10% to 22%, despite limited pCR.
Does immune activation translate into clinical benefit?
@OncoAlert #BreastCancer #bcsm
Aya Mohamed | MSc, MD 🎗 retweeted
PREDICT-HERは、T-DXdの投与を予定した進行乳癌患者を対象に、HER2-PETによって薬剤の効果を予測できるかを検討した単群第II相試験。
T-DXd開始前に18Fまたは68Ga標識affibodyを用いたHER2-PET/CTを実施し、HER2-PET陽性と陰性に分類。
主要目的は、HER2-PET陰性によるT-DXd非奏効予測の陰性的中率(NPV)が85%以上となるかの評価。
結果は、HER2-PET陰性のNPV 88.2%、15/17例で試験としてはpositive resultでした。
HER2-lowやHER2-ultralowでは、従来のIHC判定が低発現領域での再現性や測定誤差の影響を受けやすいという問題があります。さらに、IHCは採取した病変の情報しかわからないため、病変分布のヘテロジェナイティを反映しない問題があります。
一方、HER2-PETは、全身の病変におけるHER2標的の結合可能性を評価できます。つまり、T-DXdの標的となるHER2が、患者さんの体内の転移巣で実際にどの程度利用可能かを評価する可能性があります。
これまで、どうにかしてT-DXdが有効な方、無効な方を見抜けないかと思っていた段階で少し期待がある結果でした。
HER2-PET陰性例が17例しかありません。そのうち15例が非奏効であり、結果は有望ですが、NPVの推定精度には限界があります。
今後は、この技術を用いて実際に治療選択を変えるには、PET陰性患者さんにおいて、T-DXd以外の治療を選択する戦略が有効か?を前向きに検証する必要があります。例えば、HER2-low患者さんのうちPET陽性例ではT-DXdを使用し、PET陰性例では他の標的ADCや化学療法を選択するといった試験デザインです。
T-DXdはHER2発現が低い細胞にもbystander effectを介して作用し得るため、PET陰性を絶対的な無効判定とまではまだ言えないかなと思っています。
#ESMO26
PREDICT-HER #ESMO26
In 89 patients receiving T-DXd, HER2-PET negativity was associated with shorter PFS, particularly in HER2-low/zero disease.
Whole-body imaging may help capture HER2 heterogeneity beyond tissue biopsy.
@OncoAlert #BreastCancer #bcsm
Aya Mohamed | MSc, MD 🎗 retweeted
特にオラパリブ併用群のOS trendは維持されていたけれど、まだ統計学的には検証されていません。
#ESMO26
DUO-E #ESMO26
Overall Survival Signals and the Added Value of PARP Inhibition in Advanced Endometrial Cancer
@OncoAlert #ESMOAmbassadors
#ESMOcommunity @myESMO
































